AWMSG recommendations on the use of plerixafor

AWMSG has recommended the use of plerixafor (MozobilĀ®) as an option within NHS Wales in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells in myeloma patients whose cells mobilise poorly. Patients may use plerixafor if they have already failed one complete mobilisation attempt.


Continuing education and learning

The Myeloma Academy is dedicated to supporting and educating healthcare professionals to ensure patients are diagnosed quicker, best practice is shared and patients receive the best possible treatment and care.   Aided by advances in technology, the myeloma field, particularly in the last decade, has rapidly evolved both scientifically and medically. This means that the…